103 related articles for article (PubMed ID: 8692551)
21. Prevention of chemotherapy-induced emesis: the state of the art.
Roila F; Tonato M; Del Favero A
Dig Dis; 1993; 11(6):343-53. PubMed ID: 8306491
[TBL] [Abstract][Full Text] [Related]
22. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models.
Naylor RJ; Rudd JA
Oncology; 1996 Jun; 53 Suppl 1():8-17. PubMed ID: 8692557
[TBL] [Abstract][Full Text] [Related]
24. Optimal control of acute cisplatin-induced emesis.
Verweij J; de Wit R; de Mulder PH
Oncology; 1996 Jun; 53 Suppl 1():56-64. PubMed ID: 8692553
[TBL] [Abstract][Full Text] [Related]
25. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
[TBL] [Abstract][Full Text] [Related]
26. Emesis and anti-emesis.
Naylor RJ; Rudd JA
Cancer Surv; 1994; 21():117-35. PubMed ID: 8564988
[TBL] [Abstract][Full Text] [Related]
27. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
28. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
29. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
30. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
du Bois A; Vach W; Thomssen C; Karck U; Madjar H; Prömpeler H; Meerpohl HG
Acta Oncol; 1994; 33(5):531-5. PubMed ID: 7917367
[TBL] [Abstract][Full Text] [Related]
32. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
33. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
[TBL] [Abstract][Full Text] [Related]
34. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
Hainsworth JD
Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
36. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
[TBL] [Abstract][Full Text] [Related]
37. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
[TBL] [Abstract][Full Text] [Related]
39. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
[TBL] [Abstract][Full Text] [Related]
40. [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
Miyamoto Y; Yagi K; Teramachi M; Oomasa M; Tomiyama K
Gan To Kagaku Ryoho; 1999 Jan; 26(1):125-30. PubMed ID: 9987508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
